Literature DB >> 16825505

Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.

Marla Lay1, Rajan Mariappan, Jason Gotlib, Lisa Dietz, Siby Sebastian, Iris Schrijver, James L Zehnder.   

Abstract

A point mutation in the JAK2 gene, a member of the tyrosine kinase family, was recently identified and shown to be associated with several myeloproliferative disorders. Several studies identified the same JAK2 point mutation (1,849G>T), resulting in the substitution of a valine to phenylalanine at codon 617 (V617F). We developed a simple and sensitive method to detect this mutation via polymerase chain reaction and probe dissociation analysis using the LightCycler platform, and we compared this method to existing restriction fragment-length polymorphism, direct sequencing, and amplification refractory mutation system methods. We found that the LightCycler method offered advantages of speed, reliability, and more straightforward interpretation over the restriction fragment-length polymorphism and sequencing approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825505      PMCID: PMC1867612          DOI: 10.2353/jmoldx.2006.050130

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  10 in total

1.  JAK2 mutations in myeloproliferative disorders.

Authors:  Ayalew Tefferi; Terra L Lasho; Gary Gilliland
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Authors:  Ross L Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian Druker; Michael W N Deininger
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

Review 3.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.

Authors:  Ayalew Tefferi; D Gary Gilliland
Journal:  Mayo Clin Proc       Date:  2005-07       Impact factor: 7.616

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Authors:  Ayalew Tefferi; Shireen Sirhan; Terra L Lasho; Susan M Schwager; Chin-Yang Li; David Dingli; Alexandra P Wolanskyj; David P Steensma; Ruben Mesa; D G Gilliland
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

9.  JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.

Authors:  Alexandra P Wolanskyj; Terra L Lasho; Susan M Schwager; Rebecca F McClure; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

10.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

  10 in total
  10 in total

1.  Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Authors:  Jason D Merker; Carol D Jones; Stephen T Oh; Iris Schrijver; Jason Gotlib; James L Zehnder
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

2.  Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.

Authors:  Cornelis J J Huijsmans; Jeroen Poodt; Paul H M Savelkoul; Mirjam H A Hermans
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

3.  Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

Authors:  Sebastian Ochsenreither; Mark Reinwald; Eckhard Thiel; Thomas Burmeister
Journal:  Mol Diagn Ther       Date:  2010-06-01       Impact factor: 4.074

4.  Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.

Authors:  Emma Hammond; Kathryn Shaw; Benedict Carnley; Stephanie P'ng; Ian James; Richard Herrmann
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

5.  Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection.

Authors:  Weiwei Liu; Tingting Hu; Yuming Chen; Xinju Zhang; Xiaoye Gu; Ming Guan
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 6.  Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.

Authors:  Donatella Verbanac; Andrea Čeri; Iva Hlapčić; Mehdi Shakibaei; Aranka Brockmueller; Božo Krušlin; Neven Ljubičić; Neven Baršić; Dijana Detel; Lara Batičić; Lada Rumora; Anita Somborac-Bačura; Mario Štefanović; Ivana Ćelap; Alma Demirović; Roberta Petlevski; József Petrik; Marija Grdić Rajković; Andrea Hulina-Tomašković; Ivana Rako; Luciano Saso; Karmela Barišić
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

7.  Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.

Authors:  Katsuhiro Fukutsuka; Futoshi Iioka; Fumiyo Maekawa; Miho Nakagawa; Chiyuki Kishimori; Masahiko Hayashida; Shunsuke Tagawa; Takashi Akasaka; Gen Honjo; Hitoshi Ohno
Journal:  J Clin Exp Hematop       Date:  2021-05-14

8.  Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.

Authors:  Zhiyuan Wu; Hong Yuan; Xinju Zhang; Weiwei Liu; Jinhua Xu; Wei Zhang; Ming Guan
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

9.  CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms.

Authors:  Miaomiao Chen; Chunhua Zhang; Zhiqing Hu; Zhuo Li; Menglin Li; Lingqian Wu; Miaojin Zhou; Desheng Liang
Journal:  Biosensors (Basel)       Date:  2021-07-24

10.  Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms.

Authors:  Alline Didone; Luciana Nardinelli; Mariana Marchiani; Antonio Roberto Lancha Ruiz; Ariel Lais de Lima Costa; Ismael Severino Lima; Nathalia Moreira Santos; Sabri Saeed Sanabani; Israel Bendit
Journal:  Pract Lab Med       Date:  2015-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.